With an increasing number of jurisdictions enacting or contemplating reforms creating legal access to cannabis for purposes other than exclusively "medical and scientific," tensions regarding the drug conventions and evolving law and practice in Member States continue to grow.
As an increasing number of jurisdictions consider whether and how to legalize and regulate access to cannabis, tensions are growing between these initiatives and countries’ obligations under the UN drug control conventions. A groundbreaking new report produced by a coalition of legal and drug policy experts offers strategies for countries exploring regulatory approaches to cannabis to do so in ways that ensure that their domestic reforms align with their international legal obligations.
As jurisdictions enact reforms creating legal access to cannabis for purposes other than exclusively “medical and scientific,” tensions surrounding the existing UN drug treaties and evolving law and practice in Member States continue to grow. How might governments and the UN system address these growing tensions in ways that acknowledge the policy shifts underway and help to modernize the drug treaty regime itself, and thereby reinforce the UN pillars of human rights, development, peace and security, and the rule of law?
Volkskrant - De Verenigde Naties houden voor het eerst in twintig jaar een conferentie over drugs, op verzoek van drie Latijns-Amerikaanse landen die vinden dat het tijd wordt een alternatief te zoeken voor de War on Drugs.
The Lancet - On April 19–21, 2016, the UN General Assembly Special Session on Drugs (UNGASS) will convene to chart a course for the future to tackle the world's drugs problem. The 2016 UNGASS represents a rare opportunity to reassess the global approach to drugs and to move towards drug policies that more effectively address the three UN pillars of peace and security, human development, and human rights. We believe that we need a new consensus that includes a commitment to revise the range of indicators used to assess and improve drug policy effectiveness.